Tag: American Association for Thoracic Surgery (AATS)

Surgical resection is associated with superior 5-year survival compared to stereotactic body radiotherapy for early-stage lung cancer in healthy patients

[ad_1]

Newswise — Stereotactic body radiotherapy (SBRT) is being used increasingly in early-stage lung cancer. Between 2012 and 2018, the proportion of otherwise healthy patients treated with SBRT increased from 15 to 26%.

A study at the Yale University School of Medicine looked at data from the National Cancer Database for this six-year period and compared the 5-year survival rates for patients who had surgical resection and patients who elected to have SBRT. Overall, 30,658 patients were identified, including 24,729 (80.7%) who underwent surgery and 5,929 (19.3%) treated with SBRT.

In propensity-matched patients, survival favored SBRT for the first several months, but reversed after one year and long-term significantly favored surgical management (5-year survival 71.0% for surgery vs. 41.8% for SBRT). When the propensity-matched analysis was repeated to only include SBRT patients who had documented refusal of a recommended surgery, surgical management again had a superior 5-year survival with (71.4% vs. 55.9%).

The increasing usage of SBRT in otherwise healthy individuals represents a potential loss in life years for patients with early-stage NSCLC. Among patients that are eligible for either treatment, long-term survival favors surgical management, particularly for patients with a health-related life expectancy exceeding two years.

Brooks Udelsman, MD, will present this study looking at some of the reasons patients opt for SBRT, Monday, May 8, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

###

Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

ABOUT AATS

The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

[ad_2]

American Association for Thoracic Surgery (AATS)

Source link

May 8, 2023
Clinical Outcomes of more than 500 Lung Transplants using Ex vivo Lung Perfusion: A Large-Volume, Single-Center Retrospective Analysis

[ad_1]

Newswise — To compare the outcomes of patients receiving lungs transplanted after undergoing ex vivo lung perfusion (EVLP) versus those transplanted conventionally at the Toronto General Hospital, Aadil Ali, PhD, and coauthors looked at 14 years of data from the Toronto Lung Transplant Database.

Patients were separated based on whether they received lungs that underwent EVLP or whether they were transplanted conventionally (controls). They were matched 1:1 based on medical diagnosis, recipient status, recipient sex, recipient age, BMI, donor age, and calendar year. The group found no differences in the incidence of Primary Graft Dysfunction (PGD) Grade 3 at 72h, post-transplant mechanical ventilation, post-transplant hospital length of stay, intensive care unit (ICU) length of stay, allograft survival analysis, and CLAD-Free survival analysis.

Dr. Ali and his associates report that “EVLP has been successfully incorporated in our program for more than a decade and is an effective method to expand the organ donor pool without compromising post-transplant outcomes.”

Dr. Ali will present the results of this study Sunday, May 7, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

###

Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

ABOUT AATS

The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

[ad_2]

American Association for Thoracic Surgery (AATS)

Source link

May 7, 2023
Long-term Outcome of Patients with Peripheral Ground Glass Opacity Dominant Lung Cancer After Sublobar Resections

[ad_1]

Newswise — In 2011, Makoto Suzuki, MD, and a team of associates from across Japan embarked on a long-term study of the safety and efficacy of sublobar resections for ground-glass opacity–dominant (GGO) peripheral lung cancer. When the group began the study, the optimal mode of surgery for GGO–dominant peripheral lung cancer defined with thoracic thin-section computed tomography was speculated as sublobar resection but not proven. At that time, the planned sample size was 330 with the expected 5-year relapse-free survival of 98% and a threshold of 95%.

Between May 2009 and April 2011, 333 patients were enrolled from 51 institutions in Japan (median age was 62 at registration) and followed until May 6, 2021. Among that group, sublobar resections were performed in 314 patients (258 wedge resections and 56 segmentectomies), conversion lobectomies were performed in 11 patients, and eight were ineligible.

At five years, the group concluded that sublobar resection with enough surgical margin offered sufficient local control and relapse-free survival for lung cancer clinically resectable N0 staged by thin-section computed tomography with 3 or fewer peripheral lesions 2.0 cm or less amenable to sublobar resection and with a consolidation tumor ratio of 0.25 or less.

At 10 years, the group can now report the reintervention-free survival of 98.6% and the overall survival of 98.5% for the 314 patients with sublobar resections. It concludes that the long-term results from their study suggest that sublobar resection for peripheral GGO-dominant lung cancer patients is a surgical procedure that can fully cure them of the disease. The indication of other treatment options should be further investigated.

Dr. Suzuki will present this study Sunday, May 7, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

###

Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

ABOUT AATS

The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

[ad_2]

American Association for Thoracic Surgery (AATS)

Source link

May 7, 2023
Results of Early Monitoring of Circulating Tumor DNA in Resected Early-Stage Non-Small Cell Lung Cancer

[ad_1]

Newswise — Among the questions that cancer patients ask following their surgeries are, “Will it come back? Do I need additional treatment?”

Circulating tumor DNA (ctDNA) offers a possible tool for answering those questions. ctDNA found in the bloodstream comes from cancerous cells and tumors; and monitoring ctDNA in patients with resected early-stage non-small cell lung cancer (NSCLC) could aid in detecting and managing recurrence.

Aaron Dinerman, MD, Baylor University Medical Center, Baylor Scott & White System, and coauthors evaluated the impact of early real-world experience of monitoring ctDNA among these patients.

Beginning in October 2021, post-operative ctDNA was monitored for all surgically resected NSCLC patients (76) at the Baylor Medical Center. Peripheral blood samples were collected for ctDNA at 3-month intervals. Of those 76 patients, eight were positive for ctDNA. Post-operative clinical care was altered for seven of the eight; five received an earlier surveillance CT scan, and six received early PET-CT scan. Six of the ctDNA-positive patients had a biopsy-proven recurrence and were directed into therapy; two have not demonstrated radiographic evidence of recurrence but were directed into earlier interval surveillance.

The serial monitoring of ctDNA following resection of early-stage NSCLC resulted in early detection of recurrent cancer and led to early surveillance and/or unexpected medical oncology referral in seven of the eight patients with positive ctDNA. (One patient demonstrated recurrence [brain metastases] with a negative ctDNA level.) This study exemplifies the impact of ctDNA on surveillance and management in early stage resected NSCLC. Further multicenter studies are required to determine protocol-specific best practices.

Travis Martin, DO, of the University of North Texas Health Science Center, will present the results of this study and its implications Sunday, May 7, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

###

Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

ABOUT AATS

The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

[ad_2]

American Association for Thoracic Surgery (AATS)

Source link

May 7, 2023
Apixaban vs. Warfarin in Patients with an On-X Mechanical Aortic Valve

[ad_1]

Newswise — Although the On-X aortic valve and apixaban have been approved for use by the U.S. Food and Drug Administration (FDA), they had not been approved to be used together. Between May 2020 and September 2022, the PROACT Xa randomized, multicenter, open-label trial compared the direct factor Xa inhibitor apixaban (Eliquis) with warfarin in patients with bileaflet carbon aortic valves.

A total of 863 patients from 60 sites who were at least 3 months out from aortic valve replacement (AVR) were randomized 1:1 to receive apixaban 5 mg twice daily or warfarin with a target INR of 2–3. Enrolled patients had a median age of 56 years; 24% were female. Among participants, 46% had AVR in the 12 months prior to randomization, 17% had AVR along with an aortic root graft, and 16% were reoperations on the aortic valve. Most patients (93%) received 81 mg of aspirin daily with the assigned anticoagulant.

The study was discontinued on Sept. 21, 2022, at the recommendation of the PROACT Xa Data and Safety Monitoring Board based on observed higher rate of thromboembolic events (valve thrombosis and thromboembolism) in patients randomized to apixaban than warfarin.

Lars Svensson, MD, of the Cleveland Clinic, will present the results of this study Saturday, May, 6, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles, detailing the events that led to the discontinuation.

###

Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

ABOUT AATS

The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

[ad_2]

American Association for Thoracic Surgery (AATS)

Source link

May 6, 2023
Safety and Efficacy of Delaying Nighttime Lung Transplantation

[ad_1]

Newswise — Lung transplantation is routinely performed at night because of the unpredictability of donor organ procurement. Late start-times for complex operations such as lung transplantation have been associated with adverse outcomes. There are numerous reasons that delaying transplantation to the morning is preferable: Rested teams perform better; the well-being of the entire team is affected by long after-hours work; and during the day, more help is available for any intraoperative complications.

But is it safe to wait? Can cross clamp and cold ischemia times be extended? How does delaying the surgery impact the outcomes?

Samuel T. Kim and colleagues at the University of California Los Angeles hypothesized that for donors with cross clamp times occurring after 1:30 a.m., the recipient operation could be delayed until morning with acceptable outcomes. Consented adult lung transplant recipients from March 2018 to May 2022 with donor cross-clamp times between 1:30 a.m. and 5:00 a.m. were prospectively enrolled in this study (34 patients; Night cohort); and their skin incision times were set at 6:30 a.m. A control group was identified and included recipients of donors with cross clamp times occurring at any other time of day (68 patients; Day cohort).

Dr. Kim and his team examined short- and medium-term outcomes, including early mortality, a composite of post-operative complications, lengths of stay (ICU and total), 1- and 3-yr survival,) and chronic lung allograft dysfunction at 3-years between the two groups. The results for each of these comparisons were statistically similar.

The group concluded that lung transplant recipients with donor cross clamp times scheduled after 1:30 a.m. can have their operations delayed safely until 6:30 a.m. with acceptable outcomes. And in experienced lung transplant centers, adoption of such a policy may lead to alternative workflow and improved team well-being.

Dr. Kim will present this study Saturday, May, 6, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

###

Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

ABOUT AATS

The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

[ad_2]

American Association for Thoracic Surgery (AATS)

Source link

May 6, 2023
Non-elective CABG Outcomes are Adversely Impacted by COVID Infection, but not by Altered Processes of Care

[ad_1]

Newswise — As thoracic researchers consider the myriad effects of COVID-19, they are looking at the impacts of the disease on patients and treatments, as well as care and treatment during the pandemic. Emily Grimsley, MD, at the University of South Florida, and co-authors looked at the differential effects of COVID-19 active viral infection, viral convalescence, and altered care processes on coronary artery bypass grafting (CABG) outcomes.

Using data from the National COVID Cohort Collaborative (N3C) about CABG cases between 2020 and 2022, the group looked at patients who had tested negative for COVID-19, tested positive less than two weeks prior to surgery (COVID-Active infection), and tested positive more than two weeks prior to surgery. For control data, they used data from the National Surgical Quality Improvement Program (NSQIP).

The incidence of in-hospital mortality, 30-day mortality, and infectious complications were significantly higher in the COVID-Active cohort compared to the other two groups. Adjusted analyses indicated in-hospital mortality, 30- and 90-day mortality, and infectious complications were significantly greater in the COVID-Active group compared to COVID-negative patients.

Comparing the equivalent mortality data for pre-COVID and the N3C data for COVID-negative patients, Grimsley’s group concluded that although the processes of care were altered by the pandemic, patient mortality did not change for COVID-negative patients. Their results indicate it is the COVID-19 infection that caused worse outcomes. Per Dr. Grimsley, “Even though healthcare delivery was significantly altered during the pandemic, it did not negatively affect patient mortality after CABG. In line with various other studies, we did see that patients with active COVID-19 infection did have higher mortality than their COVID-negative counterparts.” The group proposes further study to define the optimal timing of CABG in those with recent COVID-19 infection.

Dr. Grimsley will present the results of this study Saturday, May 6, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

###

Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

ABOUT AATS

The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

[ad_2]

American Association for Thoracic Surgery (AATS)

Source link

May 6, 2023
Disparities in Racial/Ethnic Representation and Salary among Academic Cardiothoracic Surgeons

[ad_1]

Newswise — The American Association for Thoracic Surgery (AATS) is committed to diversity, equity, and inclusion. A wealth of data has shown that diversity in the physician workforce improves patient care, safety, physician well-being, and innovation; and fair compensation is essential to culturing a diverse workforce.

To learn more about how race and ethnicity are related to compensation, diverse group of academic cardiothoracic surgeons led by Cherie P. Erkmen, MD, of Temple University, looked at the racial and ethnic representation among academic cardiothoracic surgeons. The group also analyzed salaries of cardiothoracic surgeons based on race/ethnicity.

Dr. Erkmen and her team looked at cross-sectional data collected by Association of American Medical Colleges Faculty Data for U.S. Medical Schools, which reported academic rank, race/ethnicity, and mean and median compensation. Their analysis reveals low diversity in the cardiothoracic workforce, especially at the advanced academic rank of professor. Black/African American cardiothoracic surgeons had lower salary than their colleagues, a difference that persisted at all academic ranks. Hispanic/LatinX and Asian cardiothoracic surgeons at lower academic ranks also experienced salary disparity, but equal or greater salaries compared with their colleagues when achieving the academic ranks of associate professor or professor. According to Dr. Erkmen, “These data demonstrate that the relationship between race/ethnicity and compensation is complex. Future studies are needed to understand mechanisms of salary disparity.” Dr. Erkmen concluded, “Our profession and our patients will benefit from a diverse workforce. Hopefully our work will someday lead to the development of best practices for equitable compensation that will support all cardiothoracic surgeons.”

Dr. Erkmen will present this study on Saturday, May 6, at the AATS 103rd Annual Meeting in Los Angeles.

Ethnicity^a Overall Professors Salary comparison^b

White 65% 78%

Asian 25.2% 15% 71-102%

Hispanic/Latino 4.0% 3% 86-130%

Black/African American 3.3% 2% 76-85%

_{^a1.5% were multiple/other race and 0.4% were American Indian/Alaskan Indian.}

_{^bPercentage of the mean and median salary earned by White cardiothoracic surgeons.}

###

Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

ABOUT AATS

The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

[ad_2]

American Association for Thoracic Surgery (AATS)

Source link

May 6, 2023
The Early Outcome of Lung Transplantation from Donors who Tested Positive for COVID-19

[ad_1]

Newswise — The effects of the COVID-19 pandemic have rumbled through every piece of society, and nowhere more dramatically than in the medical communities.

Takashi Harano, MD, and colleagues at Keck Medicine, University of Southern California, analyzed lung transplantation data from April 2020 to June 2022, to identify the early outcomes for patients who received lungs from COVID-19–positive donors.

Of the 29,944 donors identified by the Organ Procurement and Transplantation Network/United Network for Organ Sharing during that time, 1,297 were COVID-19 positive (4.3%). Lungs were transplanted from 47 donors.

The recipients of allografts from those 47 donors had higher Lung Allocation Scores and more frequently underwent double lung transplantation (43/47). The post-transplant length of hospital stay, needs of Extracorporeal membrane oxygenation at 72 hours after transplantation, and survival outcomes were comparable between the two groups.

This study reports that carefully selected lung allografts from COVID-19–positive donors had comparable early post-transplant outcomes to the lung allografts from COVID-19-negative donors.

Dr. Harano will present the results of this study Saturday, May 6, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

###

Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

ABOUT AATS

The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

[ad_2]

American Association for Thoracic Surgery (AATS)

Source link

May 6, 2023
Air Quality and Lung Cancer in Wayne County, Mich.—a Large Urban/Suburban Study

[ad_1]

Newswise — Lung cancer is the most common cause of cancer-related deaths in North America. Although cigarette smoking remains the main risk factor for lung cancer development, the importance of environmental factors such as pollution and poor air quality is becoming increasingly recognized. Excessive exposure to air pollutants, frequently found in larger urban areas, can lead to negative health outcomes including lung cancer.

To understand the relationship between specific environmental pollutants and lung cancer in a large urban county in Michigan, Hollis E. Hutchings, MD, and a research group out of the Henry Ford Health System in Detroit analyzed comprehensive lung cancer information and air pollution data encompassing more than three decades. The group investigated the spatial relationship of lung cancer incidence within Wayne County over time and used air pollutant data from the U.S. Environmental Protection Agency to analyze the relationship between pollutant levels and the incidence of lung cancer.

The group identified 58,866 cases of lung cancer. There were three major clusters of lung cancer incidence in the county. The most intense clusters were in downtown Detroit and the heavily industrialized downriver area. Sulfur dioxide (SO2) had the strongest statistical correlation with lung cancer. Particulate matter 10 (PM10), nitric oxide (NO2), volatile organic compounds (VOCs) and ozone levels also had statistically significant correlations with incidence.

Based on these data, the group suggests that resident health in areas with poor air quality may benefit from targeted interventions such as campaigns for lung cancer screening and reduction of pollutants. Residential history may also be important when counseling individual patients with lung disease.

Dr. Hutchings will present the results of this study Sunday, May 6, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

###

Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

ABOUT AATS

The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

[ad_2]

American Association for Thoracic Surgery (AATS)

Source link

May 6, 2023
Valved Sano Shunt Improves Immediate Outcomes Following Norwood Operation for Hypoplastic Left Heart Syndrome

[ad_1]

Newswise — Hypoplastic left heart syndrome (HLHS) is a birth defect that affects normal blood flow through the heart. As the baby develops during pregnancy, the left side of the heart does not form correctly. The Centers for Disease Control and Prevention (CDC) estimates that each year about 1,025 babies in the United States are born with hypoplastic left heart syndrome—about one out of every 3,841 babies each year.

Although HLHS outcomes have improved tremendously with staged surgical palliation and the technical and management refinements incorporated over time, the overall 5-year survival rate is ~65%. Considerable Stage I perioperative and interstage morbidity and mortality remain, despite refinements of the surgical technique of the Norwood procedure. Two options used to circumvent the birth defect are the Blalock-Taussig (BT) shunt, which connects the right subclavian artery to pulmonary artery, and the Sano shunt, which connects directly from the right ventricle to the pulmonary artery. Although many centers have adopted the Sano shunt because it solves some of the weaknesses of the BT shunt physiology and improves survival outcomes, it has several shortcomings.

David Kalfa, MD, PhD, and associates at Columbia University Medical Center hypothesized that use of the Valved Sano (VS) during the Norwood Stage I operation would improve cardiac hemodynamics, stabilize end-organ function postoperatively, reduce cardiac events and reinterventions, and boost ventricular recovery during the initial Stage I hospitalization and interstage periods. The group reviewed 25 consecutive HLHS neonates who underwent a valved Sano (VS) Stage I operation using a femoral venous homograft and 25 consecutive HLHS neonates who underwent a standard non-valved Sano (NVS) between 2014 and 2022. Primary outcomes were ventricular function, tricuspid regurgitation, end-organ function, Sano and pulmonary artery (PA) reintervention, and survival at post-operative, discharge, interstage, and pre-Glenn time points.

This retrospective analysis indicates that the VS was associated with improved multi-organ recovery and hemodynamic stability resulting in fewer patients experiencing cardiac events, fewer PA reinterventions before Stage II, and enhanced ventricular function recovery during initial hospitalization following the Norwood operation. These beneficial associations exist without an accompanied increase in conduit reinterventions. These promising findings warrant increased use and study of the VS during the Norwood operation.

Dr. Kalfa will present this study Saturday, May 6, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

###

Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

ABOUT AATS

The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

[ad_2]

American Association for Thoracic Surgery (AATS)

Source link

May 6, 2023